Safety, efficacy and acceptability of outpatient mifepristone-misoprostol medical abortion through 70 days since last menstrual period in public sector facilities in Mexico City

Reprod Health Matters. 2015 Feb;22(44 Suppl 1):75-82. doi: 10.1016/S0968-8080(15)43825-X.


Extensive evidence exists regarding the efficacy and acceptability of medical abortion through 63 days since last menstrual period (LMP). In Mexico City's Secretariat of Health (SSDF) outpatient facilities, mifepristone-misoprostol medical abortion is the first-line approach for abortion care in this pregnancy range. Recent research demonstrates continued high rates of complete abortion through 70 days LMP. To expand access to legal abortion services in Mexico City (where abortion is legal through 12 weeks LMP), this study sought to assess the efficacy and acceptability of the standard outpatient approach through 70 days in two SSDF points of service. One thousand and one women seeking pregnancy termination were enrolled and given 200 mg mifepristone followed by 800 μg misoprostol 24-48 hours later. Women were asked to return to the clinic one week later for evaluation. The great majority of women (93.3%; 95% CI: 91.6-94.8) had complete abortions. Women with pregnancies ≤ 8 weeks LMP had significantly higher success rates than women in the 9th or 10th weeks (94.9% vs. 90.5%; p = 0.01). The difference in success rates between the 9th and 10th weeks was not significant (90.0% vs. 91.2%; p = 0.71). The majority of women found the side effects (82.9%) and the use of misoprostol (84.4%) to be very acceptable or acceptable. This study provides additional evidence supporting an extended outpatient medical abortion regimen through 10 weeks LMP.

Keywords: Mexico; medical abortion; mifepristone; misoprostol.

Publication types

  • Multicenter Study

MeSH terms

  • Abortifacient Agents, Nonsteroidal / pharmacology*
  • Abortifacient Agents, Steroidal / pharmacology*
  • Abortion, Induced / methods*
  • Abortion, Induced / psychology
  • Adolescent
  • Adult
  • Drug Combinations
  • Female
  • Humans
  • Mexico
  • Middle Aged
  • Mifepristone / pharmacology*
  • Misoprostol / pharmacology*
  • Outpatients
  • Patient Acceptance of Health Care
  • Patient Satisfaction
  • Pregnancy
  • Pregnancy Trimester, First
  • Public Sector
  • Treatment Outcome
  • Young Adult


  • Abortifacient Agents, Nonsteroidal
  • Abortifacient Agents, Steroidal
  • Drug Combinations
  • Misoprostol
  • Mifepristone